You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, February 2017
|
| DOI | 10.1186/s40425-017-0217-6 |
| Pubmed ID | |
| Authors |
Stefan N. Symeonides, Stephen M. Anderton, Alan Serrels |
| Abstract |
Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 31% |
| United Kingdom | 3 | 10% |
| Canada | 1 | 3% |
| China | 1 | 3% |
| Russia | 1 | 3% |
| Spain | 1 | 3% |
| Unknown | 13 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 59% |
| Scientists | 8 | 28% |
| Practitioners (doctors, other healthcare professionals) | 3 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| France | 1 | 2% |
| Unknown | 56 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 27% |
| Researcher | 15 | 25% |
| Student > Master | 11 | 19% |
| Student > Bachelor | 3 | 5% |
| Student > Postgraduate | 3 | 5% |
| Other | 2 | 3% |
| Unknown | 9 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 18 | 31% |
| Medicine and Dentistry | 12 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 10% |
| Agricultural and Biological Sciences | 4 | 7% |
| Immunology and Microbiology | 4 | 7% |
| Other | 5 | 8% |
| Unknown | 10 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2018.
All research outputs
#1,456,336
of 25,461,852 outputs
Outputs from Journal for Immunotherapy of Cancer
#370
of 3,436 outputs
Outputs of similar age
#28,520
of 324,151 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#7
of 27 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,436 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,151 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.